Table 1 Meta-analyses references of the studies on candidate IHC markers for survival in ESCC
From: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review
Marker | References | Publication period of involved studies | Number of eligible studies | Number of patients | Pooled HR | 95% CI |
|---|---|---|---|---|---|---|
EGFR | Yu et al. [27] | Until Nov, 2010 | 5 | 462 | 1.60 | 1.05–2.43 |
Wang et al. [28] | Until Dec, 2013 | 13 | 1150 | 1.768 | 1.039–3.007 | |
Cyclin D1 | Zhao et al. [40] | Until Apr, 2010 | 10 | 1376 | 1.78 | 1.49–2.12 |
Chen et al. [41] | Until Apr, 2012 | 12 | 1295 | 1.82 | 1.50–2.20 | |
P21 | Chen et al. [41] | Until Apr, 2012 | 7 | 683 | 1.28 | 0.70–2.33 |
P27 | Chen et al. [41] | Until Apr, 2012 | 6 | 478 | 0.51 | 0.26–1.00 |
P53 | Chen et al. [41] | Until Apr, 2012 | 20 | 2063 | 1.25 | 1.03–1.51 |
Survivin | Chen et al. [41] | Until Apr, 2012 | 4 | 295 | 1.57 | 0.91–2.69 |
Li et al. [58] | Until Mar, 2012 | 3 (nuclei) | 277 | 1.89 | 1.45–2.96 | |
2 (cytoplasm) | 113 | 0.96 | 0.16–5.69 | |||
Xia et al. [59] | Until Nov, 2014 | 8 | 573 | 1.82 | 1.43–2.30 | |
VEGF | Chen et al. [41] | Until Apr, 2012 | 16 | 1329 | 1.84 | 1.45–2.33 |
Chen et al. [71] | Until Dec, 2011 | 26 | 2043 | 1.81 | 1.57–2.10 | |
HIF-1α | Ping et al. [74] | Until Sep, 2013 | 12 | 942 | 1.78 | 1.41–2.24 |
Sun et al. [75] | Until Dec, 2011 | 16 | 1261 | 0.32 | 0.115–0.887 | |
E-cadherin | Chen et al. [41] | Until Apr, 2012 | 7 | 977 | 0.81 | 0.64–1.01 |
Xu et al. [78] | Until Jun, 2012 | 9 | 1129 | 0.72 | 0.64–0.83 | |
MTA1 | Luo et al. [94] | Until Oct, 2013 | 4 | 465 | 1.86 | 1.44–2.39 |
PD-L1 | Qu et al. [97] | Until Jul, 2016 | 7 | 1350 | 1.65 | 0.95–2.85 |
COX-2 | Chen et al. [41] | Until Apr, 2012 | 4 | 234 | 0.96 | 0.39–2.41 |
Li et al. [102] | Until Dec, 2008 | 12 | 1167 | 1.42 | 1.07–1.90 | |
OCT4 | Nagaraja et al. [103] | Until May, 2013 | 4 | 539 | 2.900 | 1.843–4.565 |